Search:


Media Contact
Annette Ballou
Email
216.658.3999
Newsroom > News
print
Juventas Therapeutics, a regenerative medicine spin-out of the Cleveland Clinic, announced a $12 million equity raise. Funds will be used to finance Phase II clinical trials of the company's JVS-100 therapy in heart and critical limb ischemia settings. Investors in Juventas include Triathlon Medical Ventures, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, Blue Chip Ventures, JumpStart, and North Coast Angel Fund.   
 
Click here to read more from Crain's Cleveland Business.

Recent News

»  Great Lakes NeuroTechnologies Receives $4.5 Million

»  Life Core Technologies Raises Seed Funding

»  Research Organics acquired by Sigma-Aldrich

»  CardioInsight Raises $7.5 Million

»  ViewRay Raises $16 Million




The 2012 Venture Report

Cleveland:
Health Care Innovation Destination

» View / Download




Sign Up for BioEnterprise eNews

Add me to your emailing list: sign up




Cleveland Medical Mart & Convention Center



The world’s only convention facility created for the health care industry.
» View More
 
Copyright © 2012 BioEnterprise   | Home | Disclaimer | Sitemap | Contact Us BioEnterprise : 11000 Cedar Avenue, Cleveland, OH 44106 | 216.658.3999